SCHEMBL3850693

SCHEMBL3850693

Clc1cccc2ccc(Br)nc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
XPO1 O14980 2/20 0.41
AR P10275 1/20 0.40
BACE1 P56817 1/20 0.39
CYP1A2 P05177 1/20 0.38
CYP2A6 P11509 1/20 0.38
LMNA P02545 4/20 0.37
PDE10A Q9Y233 1/20 0.37
KMT2A Q03164 3/20 0.36
NPC1 O15118 3/20 0.36
HSP90AA1 P07900 2/20 0.36
MEN1 O00255 2/20 0.36
AGTR1 P30556 1/20 0.36
HDAC1 Q13547 1/20 0.35
HDAC2 Q92769 1/20 0.35
HDAC8 Q9BY41 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35
NOS1 P29475 1/20 0.35
MAPT P10636 3/20 0.34
TDP1 Q9NUW8 2/20 0.34
KDM4E B2RXH2 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28801096 0.78 BACE1 (0.36) BACE1CYP2A6LMNAHSP90AA1MAPT
SCHEMBL339928 0.77 BACE1 (0.63) ARBACE1CYP1A2CYP2A6LMNA
SCHEMBL29683992 0.77 SLC40A1 (0.45) XPO1ARBACE1CYP1A2CYP2A6
SCHEMBL845037 0.77 SLC40A1 (0.45) XPO1ARBACE1CYP1A2CYP2A6
SCHEMBL30657716 0.77 BACE1 (0.63) ARBACE1CYP1A2CYP2A6LMNA
SCHEMBL57528 0.75 CCR1 (0.43) BACE1CYP2A6LMNAHSP90AA1MAPT
SCHEMBL23548885 0.74 XPO1 (0.41) XPO1ARCYP1A2CYP2A6LMNA
SCHEMBL2757274 0.74 METAP2 (0.59) XPO1ARCYP1A2AGTR1MAPT
SCHEMBL22119746 0.74 BACE1 (0.48) BACE1CYP1A2LMNAPDE10AKMT2A
SCHEMBL934781 0.74 KMT2A (0.42) XPO1ARCYP1A2CYP2A6LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122036808-A Organic electroluminescent material and device 环球展览公司 2026-05-15 CN disclosed
US-20260136752-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2026-05-14 US disclosed
WO-2024049929-A2 PANNEXIN-1 MODULATORS AND METHODS OF TREATING DISORDERS IN WHICH PANNEXIN-1 IS IMPLICATED PANNEX THERAPEUTICS INC. (US) 2024-03-07 WO disclosed
US-11198745-B2 Poly(alpha-olefin)s and methods thereof EXXONMOBIL CHEMICAL PATENTS INC. (US) 2021-12-14 US disclosed
EP-3887414-A1 POLY(ALPHA-OLEFIN)S AND METHODS THEREOF ExxonMobil Chemical Patents Inc. (US) 2021-10-06 EP disclosed
US-20200190236-A1 Poly(alpha-olefin)s and Methods Thereof EXXONMOBIL CHEMICAL PATENTS INC. 2020-06-18 US disclosed
WO-2020112547-A1 POLY(ALPHA-OLEFIN)S AND METHODS THEREOF EXXONMOBIL CHEMICAL PATENTS INC. (US) 2020-06-04 WO disclosed
CN-109475530-A For treating the aminoacyl indazole immunomodulator of autoimmune disease 洛克菲勒大学 2019-03-15 CN disclosed
CN-108699032-A Polycyclic T L R7/8 antagonists and their use in treating immune disorders 默克专利有限公司 2018-10-23 CN disclosed
CN-108558873-A A kind of aromatic amine derivant and its organic electroluminescence device 长春海谱润斯科技有限公司 2018-09-21 CN disclosed
CN-102249996-B 2-(quinoline-8-yl)carbonyl-cyclohexane-1,3-dione compounds BEIJING FAGAIYIN TECHNOLOGY CO LTD 2012-11-14 CN disclosed
CN-102249996-A 2-(quinoline-8-yl)carbonyl-cyclohexane-1,3-dione compounds BEIJING FAGAIYIN TECHNOLOGY CO LTD 2011-11-23 CN disclosed
US-7576098-B2 Heterocyclic compounds as inhibitors of factor VIIa BRISTOL-MYERS SQUIBB COMPANY (US) 2009-08-18 US disclosed
US-7576098-B2 Heterocyclic compounds as inhibitors of factor VIIa BRISTOL-MYERS SQUIBB COMPANY (US) 2009-08-18 US disclosed
US-7576098-B2 Heterocyclic compounds as inhibitors of factor VIIa BRISTOL-MYERS SQUIBB COMPANY (US) 2009-08-18 US disclosed
EP-1828152-B1 HETEROCYCLIC COMPOUNDS AS INHIBITORS OF FACTOR VIIA BRISTOL MYERS SQUIBB CO (US) 2008-08-20 EP disclosed
EP-1828152-B1 HETEROCYCLIC COMPOUNDS AS INHIBITORS OF FACTOR VIIA BRISTOL MYERS SQUIBB CO (US) 2008-08-20 EP disclosed
EP-1828152-A2 HETEROCYCLIC COMPOUNDS AS INHIBITORS OF FACTOR VIIA Bristol-Myers Squibb Company (US) 2007-09-05 EP disclosed
US-20060211720-A1 Heterocyclic compounds as inhibitors of factor VIIa BRISTOL-MYERS SQUIBB COMPANY 2006-09-21 US disclosed
WO-2006062972-A2 HETEROCYCLIC COMPOUNDS AS INHIBITORS OF FACTOR VIIA BRISTOL-MYERS SQUIBB COMPANY (US) 2006-06-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200190236-A1 Poly(alpha-olefin)s and Methods Thereof PUF60, DEGS1, POLL XPO1 4306/4885AR 3349/4885BACE1 777/4885
US-11198745-B2 Poly(alpha-olefin)s and methods thereof PUF60, DEGS1, POLL XPO1 4306/4885AR 3349/4885BACE1 777/4885
US-20260136752-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES LBR, GLRB, GLRA1 XPO1 2398/4885AR 196/4885BACE1 2180/4885
US-20060211720-A1 Heterocyclic compounds as inhibitors of factor VIIa TFPI, F7, HABP2 XPO1 1328/4885AR 3551/4885BACE1 232/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.